Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2537 : TFK-1  update : 2024/09/24
CommentHuman cell line derived from extrahepatic bile duct carcinoma. TKG0367 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Fukuda, Hiroshi
Originator Saijyo, S.
Year of deposit 2007
Original cell TKG0367
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 63 years
Tissue common bile duct
Disease name papillary adenocarcinoma,
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0367)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_2214
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 6 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 3
User's Publication 57


To topTop
Reference
5036  Kodama H, Suzuki M, Katayose Y, Shinoda M, Sakurai N, Takemura S, Yoshida H, Saeki H, Ichiyama M, Tsumoto K, Asano R, Kumagai I, Imai K, Hinoda Y, Matsuno S, Kudo T.  Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.  Cancer Immunol Immunother  2001  50(10):539-48  PubMed ID: 11776376   DOI: 10.1007/s002620100219
5035  Sakurai N, Kudo T, Suzuki M, Tsumoto K, Takemura S, Kodama H, Ebara S, Teramae A, Katayose Y, Shinoda M, Kurokawa T, Hinoda Y, Imai K, Matsuno S, Kumagai I.  SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.  Biochem Biophys Res Commun  1999  256(1):223-30  PubMed ID: 10066451   DOI: 10.1006/bbrc.1999.0263
5034  Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.  Tohoku J Exp Med  1995  177(1):61-71  PubMed ID: 8693487   DOI: 10.1620/tjem.177.61

To topTop
User's Publication
21621  Tokito F, Kiyofuji M, Choi H, Nishikawa M, Takezawa T, Sakai Y.  Modulation of hepatic cellular tight junctions via coculture with cholangiocytes enables non-destructive bile recovery.  J Biosci Bioeng  2024    PubMed ID: 38413317   DOI: 10.1016/j.jbiosc.2024.01.017
21815  Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.  NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion.  Mol Cancer Res  2024    PubMed ID: 38949523   DOI: 10.1158/1541-7786.MCR-23-1003
19596  Miaki UZU, Toshiaki TAKEZAWA  Novel Cell Culture Technology to Harvest Hepatic Metabolites Accumulated in the Bile Canaliculus-like Structures between HepG2-NIAS Cells Utilizing Crosstalk with TFK-1 Cells  Nano Biomedicine  2023  15(2):75-87    DOI: 10.11344/nano.15.75
19739  Yogo A, Masui T, Takaishi S, Masuo K, Chen R, Kasai Y, Nagai K, Anazawa T, Watanabe S, Sakamoto S, Watanabe A, Inagaki R, Nakagawa MM, Ogawa S, Seno H, Uemoto S, Hatano E.  Inhibition of dopamine receptor D1 signaling promotes human bile duct cancer progression via WNT signaling  Cancer Sci  2023  114(4):1324-1336  PubMed ID: 36441110   DOI: 10.1111/cas.15676
20980  Takahashi M, Tsuchikawa T, Hiwasa T, Nakamura T, Hontani K, Kushibiki T, Inoko K, Takano H, Hatanaka Y, Matsushita K, Matsubara H, Hoshino T, Ohtsuka M, Shimada H, Tanaka K, Nakanishi Y, Asano T, Noji T, Okamura K, Shichinohe T, Hirano S.  Identification of antibody against wingless‑type MMTV integration site family member 7B as a biliary cancer tumor marker.  Oncol Rep  2023  49(2)  PubMed ID: 36562381   DOI: 10.3892/or.2022.8471
21109  Oba M, Nakanishi Y, Mitsuhashi T, Sasaki K, Hatanaka KC, Sasaki M, Nange A, Okumura A, Hayashi M, Yoshida Y, Nitta T, Ueno T, Yamada T, Ono M, Kuwabara S, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Takayama K, Hatanaka Y, Hirano S.  CCR7 Mediates Cell Invasion and Migration in Extrahepatic Cholangiocarcinoma by Inducing Epithelial-Mesenchymal Transition.  Cancers (Basel)  2023  15(6)  PubMed ID: 36980764   DOI: 10.3390/cancers15061878
21324  Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK.  Molecular profiling reveals potential targets in cholangiocarcinoma.  World J Gastroenterol  2023  29(25):4053-4071  PubMed ID: 37476584   DOI: 10.3748/wjg.v29.i25.4053
17715  Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z.  Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance  Front Oncol  2022  12:871281  PubMed ID: 35965521   DOI: 10.3389/fonc.2022.871281
18104  Ueno G, Iwagami Y, Kobayashi S, Mitsufuji S, Yamada D, Tomimaru Y, Akita H, Asaoka T, Noda T, Gotoh K, Mori M, Doki Y, Eguchi H.  ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer  Ann Surg Oncol  2022  29(5):2899-2909  PubMed ID: 34994902   DOI: 10.1245/s10434-021-11152-1
16279  Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY.  Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer  Cancer Res Treat  2022  Aug 6  PubMed ID: 34352995   DOI: 10.4143/crt.2021.473
20697  Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K.  Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.  Toxicol In Vitro  2022  105385  PubMed ID: 35568131   DOI: 10.1016/j.tiv.2022.105385
21043  Wu WS, Chen RF, Cheng CC, Wei JL, Lin CF, You RI, Chen YC, Lee MC, Chen YC.  Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma.  Pharmaceutics  2022  14(12)  PubMed ID: 36559193   DOI: 10.3390/pharmaceutics14122698
13485  Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.  Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes  Cancer Sci  2021  112(2):828-838  PubMed ID: 33345417   DOI: 10.1111/cas.14780
20163  Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY.  ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.  Cancer Lett  2021  516:38-47  PubMed ID: 34082024   DOI: 10.1016/j.canlet.2021.05.029
14929  Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T.  Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma  Mol Cancer Ther  2021  molcanther.0015.2021  PubMed ID: 34224365   DOI: 10.1158/1535-7163.MCT-21-0015
16118  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M  Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth  FEBS Open Bio  2021  11(12):3276-329  PubMed ID: 34510808   DOI: 10.1002/2211-5463.13294
12014  Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S.  Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.  Sci Rep  2020    PubMed ID: 31969633   DOI: 10.1038/s41598-020-57806-0
12036  San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W.  Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.  Heliyon  2020    PubMed ID: 32051864   DOI: 10.1016/j.heliyon.2020.e03255
12044  Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.  Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.  Cancer Sci.  2020    PubMed ID: 31799781   DOI: 10.1111/cas.14267
12163  Aman Tedasen, Araya Khoka, Siribhorn Madla, Somchai Sriwiriyajan, Potchanapond Graidist  Anticancer effects of piperine-free Piper nigrum extract on cholangiocarcinoma cell lines  Pharmacognosy Magazine  2020      DOI: 10.4103/pm.pm_288_19
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492   DOI: 10.3390/biom10111529
13552  Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.  Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer  Cancer Res Treat  2020  52(3):945-956  PubMed ID: 32311864   DOI: 10.4143/crt.2020.080
13579  Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer  Cancer Chemother Pharmacol  2020  85(6):1063-1078  PubMed ID: 32440762   DOI: 10.1007/s00280-020-04079-z
20122  Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.  Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.  Front Immunol  2020  11:630139  PubMed ID: 33692777   DOI: 10.3389/fimmu.2020.630139
11476  Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Cell Death Dis  2019    PubMed ID: 30850583   DOI: 10.1038/s41419-019-1460-1
4244  Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.  Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.  Cancer Res Treat  2019  51(3):1167-1179  PubMed ID: 30514066   DOI: 10.4143/crt.2018.526
4245  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.  Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.  Cancer Res Treat  2019  51(3):886-900  PubMed ID: 30282449   DOI: 10.4143/crt.2018.375
11552  Yu J, Shi L, Shen X, Zhao Y.  UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals.  Biochem. Pharmacol.  2019    PubMed ID: 31085159   DOI: 10.1016/j.bcp.2019.05.017
14815  Song IH, Jeong MS, Hong HJ, Shin JI, Park YS, Woo SK, Moon BS, Kim KI, Lee YJ, Kang JH, Lee TS.  Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model  Clin Cancer Res  2019  25(20):6148-6159  PubMed ID: 31337646   DOI: 10.1158/1078-0432.CCR-19-1157
10816  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.  Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.  Oncotarget  2018  9:16400-16417  PubMed ID: 29662654   DOI: 10.18632/oncotarget.24711
10834  Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T.  Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.  Anticancer Res.  2018  38:2739-2748  PubMed ID: 29715094   DOI: 10.21873/anticanres.12516
10838  Huang CK, Iwagami Y, Zou J, Casulli S, Lu S, Nagaoka K, Ji C, Ogawa K, Cao KY, Gao JS, Carlson RI, Wands JR.  Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.  Cancer Lett.  2018  429:1-10  PubMed ID: 29733964   DOI: 10.1016/j.canlet.2018.04.041
11090  Ishigami K, Nosho K, Koide H, Kanno S, Mitsuhashi K, Igarashi H, Shitani M, Motoya M, Kimura Y, Hasegawa T, Kaneto H, Takemasa I, Suzuki H, Nakase H.  MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer.  Carcinogenesis  2018  39(9):1127-1134  PubMed ID: 29860474   DOI: 10.1093/carcin/bgy075
11166  Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M.  Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.  Ann. Surg. Oncol.  2018  25(12):3728-3737  PubMed ID: 30105440   DOI: 10.1245/s10434-018-6670-8
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867   DOI: 10.1111/cas.13829
4360  Ohashi T, Eguchi H, Kawamoto K, Konno M, Asai A, Colvin H, Ueda Y, Takaoka H, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Kobayashi S, Koseki J, Satoh T, Ogawa K, Doki Y, Mori M, Ishii H.  Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.  Oncol. Rep.  2018  39(3):1276-1282  PubMed ID: 29286150   DOI: 10.3892/or.2017.6172
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
10312  Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473   DOI: 10.3892/or.2017.5622
4099    A novel photodynamic therapy-based drug delivery system layered on a stent for treating cholangiocarcinoma  Biomedical Microdevices  2017  20:3  PubMed ID: 29164403   DOI: 10.1007/s10544-017-0249-1
5767  Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.  Oncotarget  2017  8(33):53899-53915  PubMed ID: 28903311   DOI: 10.18632/oncotarget.19108
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14528  Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.  Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree  PLoS One  2017  12(4):e0175355  PubMed ID: 28388653   DOI: 10.1371/journal.pone.0175355
14652  Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H.  Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins  Oncotarget  2017  8(26):42159-42172  PubMed ID: 28178675   DOI: 10.18632/oncotarget.15020
9515  Sakamoto T, Kobayashi S, Yamada D, Nagano H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.  A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.  PLoS ONE  2016  11:e0145985  PubMed ID: 26726879   DOI: 10.1371/journal.pone.0145985
9668  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Src as a Therapeutic Target in Biliary Tract Cancer.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758   DOI: 10.1158/1535-7163.MCT-16-0013
9700  Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.  Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.  BMC Cancer  2016  16:322  PubMed ID: 27206490   DOI: 10.1186/s12885-016-2360-8
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
14138  Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Therapeutic implication of HER2 in advanced biliary tract cancer  Oncotarget  2016  7(36):58007-58021  PubMed ID: 27517322   DOI: 10.18632/oncotarget.11157
7201  Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.  Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.  Oncol. Rep.  2015  34:2987-96  PubMed ID: 26398221   DOI: 10.3892/or.2015.4284
7429  Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509   DOI: 10.1371/journal.pone.0120545
4891  Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F.  Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.  Genes Chromosomes Cancer  2014  53(12):1033-40  PubMed ID: 25231053   DOI: 10.1002/gcc.22212
14393  Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H.  Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells  Oncol Rep  2014  31(2):983-8  PubMed ID: 24337160   DOI: 10.3892/or.2013.2922
14930  Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.  Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater  Int J Oncol  2014  44(4):1139-45  PubMed ID: 24481592   DOI: 10.3892/ijo.2014.2282
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563   DOI: 10.1111/j.1349-7006.2011.02138.x
15724  Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H.  E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma  Br J Cancer  2011  105(12):1885-93  PubMed ID: 22068819   DOI: 10.1038/bjc.2011.452
18737  Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues  J Proteome Res  2009  8(8):4092-103  PubMed ID: 19569727   DOI: 10.1021/pr900468k
15602  Guleng B, Tateishi K, Ohta M, Asaoka Y, Jazag A, Lin LJ, Tanaka Y, Tada M, Seto M, Kanai F, Kawabe T, Omata M.  Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity  J Gastroenterol   2006  41(12):1238-9  PubMed ID: 17287906   DOI: 10.1007/s00535-006-1955-2



Back Back Return Top Page